IXIMAB ® (100mg) Injection
(Infliximab 100 mg Injection)
GENERIC NAME: Infliximab 100 mg Injection
THERAPEUTIC CLASS:
Anti-TNF-α Monoclonal Antibody
INDICATIONS & DOSAGE:
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Crohn’s Disease (Adult & Pediatric)
- Fistulizing Crohn’s Disease
- Ulcerative Colitis
- Plaque Psoriasis
STORAGE:Store and transport at 2–8°C. Protect from light.
PACK SIZE: 1 glass vial/box.
DOSAGE & ADMINISTRATION:
Rheumatoid Arthritis:
The recommended dose of Iximab is 3 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 3 mg/kg every 8 weeks. Iximab should be given in combination with methotrexate. For patients who have an incomplete response, consideration may be given to adjusting the dose up to 10 mg/kg or treating as often as every 4 weeks
Ankylosing Spondylitis:
5 mg/kg IV infusion at weeks 0, 2, and 6 followed by 5 mg/kg every 8 weeks.
Crohn’s Disease / Fistulizing Crohn’s Disease:
5 mg/kg IV infusion at weeks 0, 2, and 6 followed by 5 mg/kg every 8 weeks. Dose may be increased to 10 mg/kg if response is incomplete.
Ulcerative Colitis:
5 mg/kg IV infusion at weeks 0, 2, and 6 followed by 5 mg/kg every 8 weeks.
Plaque Psoriasis:
5 mg/kg IV infusion at weeks 0, 2, and 6 followed by 5 mg/kg every 8 weeks. Treatment should be discontinued if no response is observed by Week 14.